Eli Lilly | LLY - Loan Capital


Eli Lilly reported $39.37B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Abbott USD 29.64B 19.74B Mar/2026
ALKERMES USD 1.48B 1.2B Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
AstraZeneca USD 25.96B 177M Mar/2026
Baxter International USD 8.62B 852M Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Drreddys Laboratories INR 129.19M 1.84M Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
Glaxosmithkline GBP 19.82B 203.13M Dec/2025
J&J USD 37.53B 1.91B Mar/2026
Medtronic USD 27.88B 255M Dec/2025
Merck USD 46.67B 77M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.45B 7.86B Mar/2026
Novartis USD 29.59B 5.35B Dec/2025
Novo Nordisk DKK 119.17B 231M Mar/2026
Perrigo USD 3.62B 17.5M Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
Phibro Animal Health USD 597.68M 5.92M Mar/2026
Prestige Brands USD 1.01B 40.28M Mar/2026
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Roche Holding CHF 27.43B 966M Dec/2025
Sanofi EUR 13.84B 1.88B Mar/2026
Sanofi EUR 15.72B 150.06M Dec/2025
United Therapeutics USD 100M 100M Jun/2024
Zoetis USD 9.04B 3M Mar/2026